header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

REDUCTION IN BLOOD TRANSFUSION RATES AFTER PRIMARY HIP AND KNEE AND ARTHROPLASTY IN A REGIONAL ELECTIVE ORTHOPAEDIC CENTRE.

7th Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Lisbon - 4-7 June, 2005



Abstract

Aim: To audit blood transfusion practice in primary total hip arthroplasty (THA) and primary total knee arthroplasty (TKA) after introduction of more stringent blood transfusion criteria.

Methods: A retrospective survey was carried out for all THR and TKR. Data was collected over a period of four months with a blood transfusion criteria of haemoglobin (Hb) concentration of 8.0 g/dl and below. This was compared against a three month period after the reduction in the blood transfusion criteria to a Hb concentration of 7.0 g/dl and below. An analysis of all pre-operative and post-operative (day-2 post-op) Hb concentrations was performed. The post-transfusion Hb concentration was recorded 1-day post transfusion.

Results: A total 539 TKA and 521 THA were performed. Following the new blood transfusion protocol the rate of blood transfusion was significantly reduced from 9.4% to 3.6% for TKA, and from 28% to 12.8% for THA.

Conclusion: A significant reduction in transfusion rates is achieved in TKA and THA by introduction of a Hb concentration 7.0 g/dl as a trigger for blood transfusion. This new trigger is based on the current body of evidence available and is integrated in to well defined care pathway. A 50% reduction in donated blood is predicted in the UK in 2007 if vCJD testing is enforced. We feel early redressing of blood transfusion practice in the UK is advised if we are to avoid a catastrophic reduction in our TKA and THA capacity.

Theses abstracts were prepared by Professor Roger Lemaire. Correspondence should be addressed to EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.